UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033376
Receipt number R000038036
Scientific Title Observational Multicenter Study of Relationship between Peripheral Neuropathy and Effectiveness in 2nd Line Therapy for Unresectable Advanced Gastric Cancer
Date of disclosure of the study information 2018/09/15
Last modified on 2020/07/13 15:49:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observational Multicenter Study of Relationship between Peripheral Neuropathy and Effectiveness in 2nd Line Therapy for Unresectable Advanced Gastric Cancer

Acronym

IVY Study

Scientific Title

Observational Multicenter Study of Relationship between Peripheral Neuropathy and Effectiveness in 2nd Line Therapy for Unresectable Advanced Gastric Cancer

Scientific Title:Acronym

IVY Study

Region

Japan


Condition

Condition

Gastric Cancer

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Examination of relationship between peripheral neuropathy and effectiveness in 2nd line therapy for unresectable advanced gastric cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

relationship between frequency of peripheral neuropathy and effectiveness of chemotherapy

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)This is a case of unresectable or recurrent gastric cancer histologically confirmed to be the primary adenocarcinoma of the stomach.
2)Patient's age is over than 20 years old
3)Cases with Performance Status (PS) of 0-2 in ECOG
4)Patients who have been fully informed of this study and have given written informed consent
5)Patients resisted first line chemotherapy consisted of fluorinated pyrimidine anticancer drugs (e.g., 5-FU, S-1, capecitabine, UFT) and platinum anticancer drugs (cisplatin or oxaliplatin) for unresectable or recurrent gastric cancer.

Key exclusion criteria

1)Patient's prognosis is within three months
2)With severe complications (angina pectoris, myocardial infarction and arrhythmia) and uncontrollable DM, blood hypertension and bleeding tendency
3)History of serious allergic reaction and with serious drug allergy
4)With clinically relevant mental disorder to be unable to answer questionnaires
5)Patients for whom the attending physician considered enrollment in the study inappropriate

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Hiroaki
Middle name
Last name Tanioka

Organization

Kawasaki Medical School

Division name

Department of Clinical Oncology

Zip code

7010192

Address

577 Matsushima, Kurashiki City Okayama 701-0192, Japan

TEL

0864621111

Email

tanioka@med.kawasaki-m.ac.jp


Public contact

Name of contact person

1st name Hiroaki
Middle name
Last name Tanioka

Organization

Kawasaki Medical School

Division name

Department of Clinical Oncology

Zip code

7010192

Address

577 Matsushima, Kurashiki City Okayama 701-0192, Japan

TEL

0864621111

Homepage URL


Email

tanioka@med.kawasaki-m.ac.jp


Sponsor or person

Institute

Kawasaki Medical School

Institute

Department

Personal name



Funding Source

Organization

Kawasaki Medical School

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kawasaki Medical School

Address

577 Matsushima, Kurashiki City Okayama 701-0192, Japan

Tel

0864621111

Email

kmsrec@med.kawasaki-m.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 09 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 08 Month 01 Day

Date of IRB

2018 Year 09 Month 10 Day

Anticipated trial start date

2018 Year 09 Month 01 Day

Last follow-up date

2022 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

none


Management information

Registered date

2018 Year 07 Month 12 Day

Last modified on

2020 Year 07 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038036


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name